1 ressive spasticity, exaggerated reflexes and muscular weakness.

2 sustain transmitter release that resulted in muscular weakness.

3 g such as paralysis, movement disorders, and muscular weakness.

4                 Patients develop progressive muscular weakness and atrophy, and no effective therapy

5                                          The muscular weakness and fatigability associated with myast

6                      Data herein details the muscular weakness and wasting exhibited by D2.mdx skelet

7 tivation within the spinal cord, accelerated muscular weakness, and a significant decrease in median

8 KO mice showed electrophysiological defects, muscular weakness, and hypersensitivity to mechanical st

9  short-living hSOD1/rag2 mice is preceded by muscular weakness as early as one month before death.

10 Follow-up investigations showed a persistent muscular weakness at 60 days, 6 months, and 1 year after

11 (RBM) is a rare disorder causing progressive muscular weakness characterized by aggresome-like inclus

12 LT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses

13 lso fatigue, infusion-related reactions, and muscular weakness in RADIUS-P.

14                                              Muscular weakness in the first year after transplantatio

15 hic skeletal muscle disease characterized by muscular weakness of proximal dominance, hypotonia, and

16 up of myopathies associated with progressive muscular weakness that are characterized by the presence

17 scle acetylcholine receptor (AChR) cause the muscular weakness that characterizes MG and its animal m